相关实验视频
Updated: Jul 2, 2025

05:39
Spontaneous Murine Model of Anaplastic Thyroid Cancer
Published on: February 3, 2023
1.6K
RAS-突变细胞学上不确定的甲状腺结节:在积极监测下恶性病发率和行为
Hannah J Sfreddo1, Elizabeth S Koh1, Karena Zhao1
1Head and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Thyroid : official journal of the American Thyroid Association
|February 26, 2024
概括
大多数RAS突变性不确定性甲状腺结节 (ITNs) 在主动监测 (AS) 管理下显示稳定性,生长和恶性瘤的发病率较低. 对所有RAS突变ITN的立即手术可能是一个低价值的做法.
科学领域:
- 内分泌学 在内分泌学.
- 在瘤学瘤学.
- 基因组学就是基因组学.
背景情况:
- 基因组分析有助于确定不确定的甲状腺结节 (ITN) 的风险分层.
- 在良性和恶性甲状腺结核中存在RAS基因突变.
- 长期RAS突变ITN的行为尚不清楚,往往导致立即手术.
研究的目的:
- 描述RAS突变ITN的瘤生长动力学,这些ITN在主动监测 (AS) 管理下进行管理.
- 为了检查经过手术切除的RAS突变ITN的组织病理学诊断.
- 评估所有RAS突变ITN立即手术的必要性.
主要方法:
- 追溯队列研究分析了来自两个队列的超声波 (美国) 和组织病理学数据:AS下的RAS突变ITN和那些经过立即手术管理的ITN.
- AS队列:≥3个月的随访,≥2次US扫描;成长定义为≥72%的瘤体积变化.
- 立即手术队列:病理诊断和长期结果的分析.
主要成果:
- 在AS队列 (63个结节) 中,平均23个月的增长率为19.0%;81.0%保持稳定.
- 来自AS队伍的6个手术切除的结节中,只有1个是恶性.
- 在即时手术队列中 (209个结节),33%是恶性,大多数是低风险的.
结论:
- 在主动监测下管理的RAS突变ITN在长时间内表现出主要稳定的瘤行为.
- 对所有RAS突变ITN的立即外科切除似乎是一个低价值的做法.
- 需要进一步的研究,以指导选择RAS突变ITN的积极监测与立即手术.
相关概念视频
The Ras Gene
6.2K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
6.2K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Mutagenicity and Carcinogenicity
1.3K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.3K

